Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Share-based Compensation (2022 - 2025)

Corvus Pharmaceuticals has reported Share-based Compensation over the past 4 years, most recently at $1.6 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $1.6 million for Q4 2025, up 93.6% from a year ago — trailing twelve months through Dec 2025 was $5.3 million (up 77.43% YoY), and the annual figure for FY2025 was $5.3 million, up 77.49%.
  • Share-based Compensation for Q4 2025 was $1.6 million at Corvus Pharmaceuticals, up from $1.2 million in the prior quarter.
  • Over the last five years, Share-based Compensation for CRVS hit a ceiling of $1.6 million in Q4 2025 and a floor of $492000.0 in Q1 2023.
  • Median Share-based Compensation over the past 4 years was $711000.0 (2024), compared with a mean of $823312.5.
  • Biggest five-year swings in Share-based Compensation: plummeted 33.42% in 2023 and later skyrocketed 93.6% in 2025.
  • Corvus Pharmaceuticals' Share-based Compensation stood at $620000.0 in 2022, then fell by 7.74% to $572000.0 in 2023, then surged by 42.13% to $813000.0 in 2024, then skyrocketed by 93.6% to $1.6 million in 2025.
  • The last three reported values for Share-based Compensation were $1.6 million (Q4 2025), $1.2 million (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.